Ratings Nutex Health Inc. OTC Markets

Equities

Market Closed - OTC Markets Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
0.7456 ^USD	+0.76%		+4.72%	-88.35%

May. 09	Earnings Flash (NUTX) NUTEX HEALTH Posts Q1 Revenue $67.5M	MT
May. 09	Nutex Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.

	1st Jan change	Capi.	ESG Refinitiv
NUTEX HEALTH INC.	-88.35%	37.07M	-
HCA HEALTHCARE, INC.	+17.74%	83.47B	C+
CVS HEALTH CORPORATION	-29.66%	69.72B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.70%	26.22B	C+
FRESENIUS SE & CO. KGAA	+3.60%	17.69B	A-
LABCORP HOLDINGS INC.	-12.16%	16.83B	B
QUEST DIAGNOSTICS INCORPORATED	+2.47%	15.7B	A-
NATERA, INC.	+74.82%	13.45B	C-
TENET HEALTHCARE CORPORATION	+73.52%	12.81B	C+
REDE D'OR SÃO LUIZ S.A.	+0.76%	12.69B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality